A recent study reported that trametinib-induced ID1 reduction helps create a less immunosuppressive tumor microenvironment and promotes the synergistic effect of trametinib combined with PD-1/PD-L1 blockade in lung adenocarcinoma, suggesting trametinib as a therapeutic alternative to target ID1 directly [89]. Here, CD274 is linked to lung adenocarcinoma.